Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.
Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T, Sugiyama H. Iiyama T, et al. Among authors: sugiyama h. Microbiol Immunol. 2007;51(5):519-30. doi: 10.1111/j.1348-0421.2007.tb03940.x. Microbiol Immunol. 2007. PMID: 17579261 Free article. Clinical Trial.
Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells.
Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, Kawakami M, Asada M, Kanato K, Motomura M, Murakami M, Fujioka T, Masuda T, Kim EH, Tsuboi A, Oka Y, Soma T, Ogawa H, Sugiyama H. Hosen N, et al. Among authors: sugiyama h. Br J Haematol. 2002 Feb;116(2):409-20. doi: 10.1046/j.1365-2141.2002.03261.x. Br J Haematol. 2002. PMID: 11841446 Free article.
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.
Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H. Elisseeva OA, et al. Among authors: sugiyama h. Blood. 2002 May 1;99(9):3272-9. doi: 10.1182/blood.v99.9.3272. Blood. 2002. PMID: 11964293 Free article.
Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers.
Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, Yao M, Takahashi E, Nakano Y, Hirabayashi H, Shintani Y, Oka Y, Tsuboi A, Hosen N, Asada M, Fujioka T, Murakami M, Kanato K, Motomura M, Kim EH, Kawakami M, Ikegame K, Ogawa H, Aozasa K, Kawase I, Sugiyama H. Oji Y, et al. Among authors: sugiyama h. Int J Cancer. 2002 Jul 20;100(3):297-303. doi: 10.1002/ijc.10476. Int J Cancer. 2002. PMID: 12115544
Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
Ogawa H, Soma T, Hosen N, Tatekawa T, Tsuboi A, Oji Y, Tamaki H, Kawakami M, Ikegame K, Murakami M, Fujioka T, Kim EH, Oka Y, Sugiyama H. Ogawa H, et al. Among authors: sugiyama h. Transplantation. 2002 Jul 27;74(2):236-43. doi: 10.1097/00007890-200207270-00015. Transplantation. 2002. PMID: 12151737
Antilung cancer effect of WT1-specific cytotoxic T lymphocytes.
Makita M, Hiraki A, Azuma T, Tsuboi A, Oka Y, Sugiyama H, Fujita S, Tanimoto M, Harada M, Yasukawa M. Makita M, et al. Among authors: sugiyama h. Clin Cancer Res. 2002 Aug;8(8):2626-31. Clin Cancer Res. 2002. PMID: 12171894
The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.
Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Oji Y, Oka Y, Sugiyama H. Ogawa H, et al. Among authors: sugiyama h. Blood. 2003 Mar 1;101(5):1698-704. doi: 10.1182/blood-2002-06-1831. Epub 2002 Oct 24. Blood. 2003. PMID: 12406915 Free article.
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: sugiyama h. Cancer Immunol Immunother. 2002 Dec;51(11-12):614-20. doi: 10.1007/s00262-002-0328-9. Epub 2002 Oct 18. Cancer Immunol Immunother. 2002. PMID: 12439606 Free PMC article.
2,735 results